Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Imageens raises funds to launch first two products

15 Apr 2021 (Last Updated April 16th, 2021 12:18)

Medical artificial intelligence (AI) startup Imageens has secured $1.4m (€1.2m) in seed financing to launch its first two products.

Imageens raises funds to launch first two products
The latest funding will aid the company in expediting the development and marketing of its products, ArtFun+ and LABEL. Credit: Ignacio DG from Pixabay.

Medical artificial intelligence (AI) startup Imageens has secured $1.4m (€1.2m) in seed financing to launch its first two products.

The funding round was led by Anaxago with participation from Business Angels ds Grandes Ecoles (BADGE), Coalescence and existing investors of Imageens.

The precise medical imaging data provided by Imageens’ software solutions help radiologists, cardiologists and vascular surgeons to make tailored decisions and improve the cardiovascular risk evaluations of patients.

The latest funding will aid the French company in expediting the development and marketing of ArtFun+, an AI and prognostic biomarker software for cardiovascular imaging, as well as LABEL, an algorithmic solution that supports automatic classification and enhancement of medical imaging data.

Furthermore, the financing round will permit Imageens to expand its team with key research and development talents, as well as build its commercial team for the scaling and deployment of its software solutions.

Imageens CEO Robert Baldwin said: “We are delighted to have been able to quickly complete this round table in collaboration with Anaxago.

“We will be able to announce the launch of several strategic projects as well as key hires in the coming months, which will be the cornerstones of Imageens’ development over the next few years.”

ArtFun+ was developed from the US National Institute of Health-funded Multi-Ethnic Study of Atherosclerosis, which analysed the predictive ability of imaging biomarkers on a multi-ethnic cohort made up of 3,675 patients across the country.

The study showed that the imaging biomarkers of ArtFun+ were highly predictive of death and hard cardiovascular in patients between the ages of 45 and 84 years.

Imageens is currently working on obtaining US Food and Drug Administration approval and CE clearance for ArtFun+ in routine cardiovascular care to complement cardiac MRI exams with cardiovascular risk biomarkers. This could provide better follow up and surgical decisions in ischemic cardiopathies, acute coronary syndrome and aortic aneurysms.